Klaira (Dienogest, Estradiol Valerate | Estradiol Valerate | Lactose Monohydrate)

The estradiol component suppresses the mid‑cycle surge of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), while dienogest, a progestogen, reinforces this suppression. Together they prevent ovulation, thicken cervical mucus, and alter the endometrium, reducing the likelihood of fertilisation and implantation.

The dosing regimen for Klaira is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet according to the schedule provided on the prescription label.

Klaira is contraindicated in pregnancy and must not be used by women who are pregnant or suspect they might be. It is also not recommended during breastfeeding unless the prescriber determines the benefits outweigh potential risks.

To order Klaira, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Klaira contains dienogest and estradiol valerate, offering a specific estrogen‑progestogen balance that may provide a different side‑effect profile compared with products containing ethinyl estradiol and other progestins. Clinical choice depends on individual risk factors, tolerability and physician preference.

Klaira tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Klaira is taken orally, usually once daily at the same time each day, with or without food, following the dosing schedule indicated by the prescriber.

Serious risks include venous thromboembolism, deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, and severe allergic reactions. Patients should seek immediate medical attention if they experience symptoms such as leg pain, shortness of breath, chest pain, or signs of an allergic reaction.

Klaira should not be used by women who are pregnant, have a history of thromboembolic disorders, are smokers over 35 years of age, have uncontrolled hypertension, have severe liver disease, or have known hypersensitivity to any of its ingredients.